Midtown Biotech Dianthus Therapeutics Launches $625M Stock Offering to Advance Autoimmune Drug Pipeline

Dianthus Therapeutics, a clinical-stage biotechnology firm headquartered in Midtown Manhattan’s Times Square, has announced a public offering of up to $625 million in stock to accelerate its development of treatments targeting autoimmune and inflammatory disorders. The company plans to sell 7.3 million shares at $81 each, with the offering expected to close by March 12.

Specializing in therapies for neuropathies—a group of inflammatory diseases causing nerve damage—Dianthus aims to deploy the capital raised to fund ongoing clinical and pre-clinical programs, commercial preparedness, and general corporate needs. The company also maintains a research site in Waltham, Massachusetts.

Dianthus went public in 2023 through a reverse merger with Cambridge-based Magenta Therapeutics, marking its entry into the public markets amid growing investor interest in biotech innovation. Despite ending 2025 with $514.4 million in cash and investments, Dianthus reported a net loss of $162.3 million, nearly doubling from $85 million the previous year. This loss largely reflects a 75% surge in research and development expenses, driven by increased clinical trial activity and development costs.

The sizable stock offering underscores Dianthus’ commitment to advancing its pipeline amid a competitive landscape, as autoimmune disease treatments remain a critical focus area within biotech. While a company spokesperson declined further comment, this capital raise positions Dianthus to sustain its research momentum and prepare for eventual commercialization. For New York’s growing biotech sector, Dianthus represents a prominent example of local firms pushing the frontier in therapeutic innovation.